CA Patent

CA3102967A1 — Composition and method for inhalation

Assigned to Mannkind Corp · Expires 2019-12-12 · 6y expired

What this patent protects

A prostaglandin composition and method for treating pulmonary arterial hypertension is disclose. The composition is based on diketopiperazine for pulmonary inhalation.

USPTO Abstract

A prostaglandin composition and method for treating pulmonary arterial hypertension is disclose. The composition is based on diketopiperazine for pulmonary inhalation.

Drugs covered by this patent

Patent Metadata

Patent number
CA3102967A1
Jurisdiction
CA
Classification
—
Expires
2019-12-12
Drug substance claim
No
Drug product claim
No
Assignee
Mannkind Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.